

## Highlights of This Issue 5395

### SPECIAL FEATURES

#### CCR Translations

**5397** Who's Eligible Anyway? Risk Modeling for Clinical Trial Accrual

Kathryn F. Mileham and Edward S. Kim  
*See related article, p. 5408*

**5400** Bringing Blood-Based Molecular Testing to the Clinic

Filip Janku and Razelle Kurzrock  
*See related article, p. 5564*

#### Molecular Pathways

**5403** Molecular Pathways: Targeting Steroid Receptor Coactivators in Cancer

David M. Lonard and Bert W. O'Malley

#### Review

**5408** Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve Accrual

Holly A. Massett, Grace Mishkin, Larry Rubinstein, S. Percy Ivy, Andrea Denicoff, Elizabeth Godwin, Kate DiPiazza, Jennifer Bolognese, James A. Zwiebel, and Jeffrey S. Abrams  
*See related commentary, p. 5397*

#### CCR Focus

**5418** Multiple Myeloma: Multiplying Therapies

Susan E. Bates

**5419** Progress and Paradigms in Multiple Myeloma



Kenneth C. Anderson

**5428** New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma

Ola Landgren and S. Vincent Rajkumar

**5434** Gene Expression Profiles in Myeloma: Ready for the Real World?

Raphael Szalat, Herve Avet-Loiseau, and Nikhil C. Munshi

**5443** Integration of Novel Agents into the Care of Patients with Multiple Myeloma

Robert Z. Orlowski and Sagar Lonial

**5453** Immune Therapies in Multiple Myeloma

Shaji K. Kumar and Kenneth C. Anderson

### CANCER THERAPY: CLINICAL

**5461** Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma



Toni K. Choueiri, Mayer N. Fishman, Bernard Escudier, David F. McDermott, Charles G. Drake, Harriet Kluger, Walter M. Stadler, Jose Luis Perez-Gracia, Douglas G. McNeel, Brendan Curti, Michael R. Harrison, Elizabeth R. Plimack, Leonard Appleman, Lawrence Fong, Laurence Albiges, Lewis Cohen, Tina C. Young, Scott D. Chasalow, Petra Ross-Macdonald, Shivani Srivastava, Maria Jure-Kunkel, John F. Kurland, Jason S. Simon, and Mario Sznol

**5472** The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects

Aaron S. Mansfield, Michelle A. Rudek, Diana Vulih, Gary L. Smith, Pamela Jo Harris, and S. Percy Ivy, on behalf of the NCI Organ Dysfunction Working Group

### PERSONALIZED MEDICINE AND IMAGING

**5480** Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma

Liqiang Xi, Trinh Hoc-Tran Pham, Eden C. Payabyab, Richard M. Sherry, Steven A. Rosenberg, and Mark Raffeld

**5487** Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Benjamin Weide, Alexander Martens, Jessica C. Hassel, Carola Berking, Michael A. Postow, Kees Bisschop, Ester Simeone, Johanna Mangana, Bastian Schilling, Anna Maria Di Giacomo, Nicole Brenner, Katharina Kähler, Lucie Heinzerling, Ralf Gutzmer, Armin Bender, Christoffer Gebhardt, Emanuela Romano, Friedegund Meier, Peter Martus, Michele Maio, Christian Blank, Dirk Schadendorf, Reinhard Dummer, Paolo A. Ascierto, Geke Hospers, Claus Garbe, and Jedd D. Wolchok

**5497** Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients



Maria Schwaederle, Hatim Husain, Paul T. Fanta, David E. Piccioni, Santosh Kesari, Richard B. Schwab, Sandip P. Patel, Olivier Harismendy, Megumi Ikeda, Barbara A. Parker, and Razelle Kurzrock



# Table of Contents

**5506 Noninvasive Detection of Metastases and Follicle Density in Ovarian Tissue Using Full-Field Optical Coherence Tomography**

Inge T.A. Peters, Paulien L. Stegehuis, Ronald Peek, Florine L. Boer, Erik W. van Zwet, Jeroen Eggemont, Johan R. Westphal, Peter J.K. Kuppen, J. Baptist Trimbos, Carina G.J.M. Hilders, Boudewijn P.F. Lelieveldt, Cornelis J.H. van de Velde, Tjalling Bosse, Jouke Dijkstra, and Alexander L. Vahrmeijer

**5514 High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer**

Carla L. Alves, Daniel Elias, Maria Lyng, Martin Bak, Tove Kirkegaard, Anne E. Lykkesfeldt, and Henrik J. Ditzel

## CANCER THERAPY: PRECLINICAL

**5527 The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models**



Sen Zhang, Rana Anjum, Rachel Squillace, Sara Nadworny, Tianjun Zhou, Jeff Keats, Yaoyu Ning, Scott D. Wardwell, David Miller, Youngchul Song, Lindsey Eichinger, Lauren Moran, Wei-Sheng Huang, Shuangying Liu, Dong Zou, Yihan Wang, Qurish Moheemad, Hyun Gyung Jang, Emily Ye, Narayana Narasimhan, Frank Wang, Juan Miret, Xiaotian Zhu, Tim Clackson, David Dalgarno, William C. Shakespeare, and Victor M. Rivera

**5539 The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer**

Richard J. Rebello, Eric Kusnadi, Donald P. Cameron, Helen B. Pearson, Analia Lesmana, Jennifer R. Devlin, Denis Drygin, Ashlee K. Clark, Laura Porter, John Pedersen, Shahneen Sandhu, Gail P. Risbridger, Richard B. Pearson, Ross D. Hannan, and Luc Furic

## BIOLOGY OF HUMAN TUMORS

**5553 Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma**

Laurence Feldmeyer, Courtney W. Hudgens, Genevieve Ray-Lyons, Priyadharsini Nagarajan, Phyu P. Aung, Jonathan L. Curry, Carlos A. Torres-Cabala, Barbara Mino, Jaime Rodriguez-Canales, Alexandre Reuben, Pei-Ling Chen, Jennifer S. Ko, Steven D. Billings, Roland L. Bassett, Ignacio I. Wistuba, Zachary A. Cooper, Victor G. Prieto, Jennifer A. Wargo, and Michael T. Tetzlaff

**5564 Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights**



**Heterogeneity in Neuroblastoma**

Mathieu Chicard, Sandrine Boyault, Leo Colmet Daage, Wilfrid Richer, David Gentien, Gaëlle Pierron, Eve Lapouble, Angela Bellini, Nathalie Clement, Isabelle Iacono, Stéphanie Bréjon, Marjorie Carrere, Cécile Reyes, Toby Hocking, Virginie Bernard, Michel Peuchmaur, Nadège Corradini, Cécile Faure-Contier, Carole Coze, Dominique Plantaz, Anne Sophie Defachelles, Estelle Thebaud, Marion Gambart, Frédéric Millot, Dominique Valteau-Couanet, Jean Michon, Alain Puisieux, Olivier Delattre, Valérie Combaret, and Gudrun Schleiermacher

See related commentary, p. 5400

**5574 Human Microbiome *Fusobacterium Nucleatum* in Esophageal Cancer Tissue Is Associated with Prognosis**

Kensuke Yamamura, Yoshifumi Baba, Shigeki Nakagawa, Kosuke Mima, Keisuke Miyake, Kenichi Nakamura, Hiroshi Sawayama, Koichi Kinoshita, Takatsugu Ishimoto, Masaaki Iwatsuki, Yasuo Sakamoto, Yoichi Yamashita, Naoya Yoshida, Masayuki Watanabe, and Hideo Baba

**5582 Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group**

Ariadne H.A.G. Ooms, Samantha Gadd, Daniela S. Gerhard, Malcolm A. Smith, Jaime M. Guidry Auvil, Daoud Meerzaman, Qing-Rong Chen, Chih Hao Hsu, Chunhua Yan, Cu Nguyen, Ying Hu, Yussanne Ma, Zusheng Zong, Andrew J. Mungall, Richard A. Moore, Marco A. Marra, Vicki Huff, Jeffrey S. Dome, Yueh-Yun Chi, Jing Tian, James I. Geller, Charles G. Mullighan, Jing Ma, David A. Wheeler, Oliver A. Hampton, Amy L. Walz, Marry M. van den Heuvel-Eibrink, Ronald R. de Krijger, Nicole Ross, Julie M. Gastier-Foster, and Elizabeth J. Perlman

**5592 CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy**



Shujie Zhao, Chen Chen, Katherine Chang, Anand Karnad, Jaishree Jagirdar, Addanki P. Kumar, and James W. Freeman

**5605 Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics**

Scott M. Haake, Jiannong Li, Yun Bai, Fumi Kinose, Bin Fang, Eric A. Welsh, Roy Zent, Jasreman Dhillon, Julio M. Pow-Sang, Y. Ann Chen, John M. Koomen, W. Kimryn Rathmell, Mayer Fishman, and Eric B. Haura

# Table of Contents

## LETTERS TO THE EDITOR

### 5617 Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials—Letter

Mogens Groenvold, Neil K. Aaronson, Anne-Sophie E. Darlington, Deborah Fitzsimmons, Eva Greimel, Bernhard Holzner, Jaap C. Reijneveld, Krzysztof A. Tomaszewski, Irma Verdonck-de Leeuw, and Lonneke van de Poll-Franse, on behalf of the EORTC Quality of Life Group

### 5618 Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials—Response

Paul G. Kluetz, Elektra J. Papadopoulou, Laura Lee Johnson, Martha Donoghue, Virginia E. Kwitkowski, Wen-Hung Chen, Rajeshwari Sridhara, Ann T. Farrell, Patricia Keegan, Geoffrey Kim, and Richard Pazdur

## CORRECTION


### 5619 Correction: The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy—Response

 AC icon indicates Author Choice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

## ABOUT THE COVER

The cover shows immunohistochemical staining of tumor-associated lymphocytes in a tumor biopsy of a nivolumab-treated patient with mRCC. Immunohistochemical staining shows enrichment in CD3<sup>+</sup> (brown) and a modest enrichment in CD4<sup>+</sup> (purple) cells at cycle 2, day 8 of nivolumab treatment relative to baseline (not shown). FoxP3 (nuclei, red) stain is also included. For details, see the article by Choueiri and colleagues on page 5461 of this issue.



# Clinical Cancer Research

**22 (22)**

*Clin Cancer Res* 2016;22:5395-5619.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/22/22>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/22/22>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.